Evidence map›Paper›PMID 41266854›Full record

ArticleBritish journal of cancer2026

Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.

Yiyue Zhu, Elaheh Zarean, Danmeng L Li, Robert L O'Reilly, Ian D Davis, Renea A Taylor, Arun A Azad, Damien M Bolton, Nathan Papa, Nathan Lawrentschuk and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yiyue ZhuPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Elaheh ZareanPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Danmeng L LiPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Robert L O'ReillyPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Ian D DavisEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.ORCID http://orcid.org/0000-0002-9066-8244
Renea A TaylorMonash Biomedicine Discovery Institute, Department of Physiology, Monash University, Clayton, VIC, Australia.
Arun A AzadDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Damien M BoltonDepartment of Urology, Austin Health, Melbourne, VIC, Australia.
Nathan PapaDepartment of Urology, Austin Health, Melbourne, VIC, Australia.
Nathan LawrentschukEJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC, Australia.
Robert J MacInnisCentre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-1627-5047
Roger L MilnePrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Graham G GilesPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.ORCID http://orcid.org/0000-0003-4946-9099
Melissa C SoutheyPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Pierre-Antoine DuguéPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia. pierre-antoine.dugue@monash.edu.ORCID http://orcid.org/0000-0003-2736-3023

Funding

Department of Health | National Health and Medical Research Council (NHMRC) GNT2017325
6 · The paper itself

Abstract

backgroundProstate-specific antigen (PSA) recurrence after radical prostatectomy signifies increased risk of metastasis and death from prostate cancer. Traditional clinical metrics may not accurately capture the underlying biological heterogeneity of the tumour, which might be improved by consideration of epigenetic biomarkers.

methodsThis study included 293 Australian participants with prostate cancer treated with radical prostatectomy (mean age: 64 years, Gleason score ≥7: 91%). Fourteen tumour DNA methylation-based signatures of aggressiveness and cell division were calculated. The association of epigenetic signatures with clinical variables were assessed using linear regression and risk ratios for PSA recurrence were assessed using modified Poisson regression.

resultsMost epigenetic signatures were strongly associated with age, Gleason score, and tumour stage but not with serum PSA levels at diagnosis. Associations were also found with risk of PSA recurrence, with increased risks ranging from 1% to 17% per SD for signatures of clinical variables and 17% to 33% for cell division scores, after adjusting for the main clinicopathological variables. The strongest association was observed for the cell division score RepliTali.

conclusionProstate cancer tissue DNA methylation-based signatures of aggressiveness and cell division were associated with elevated risk of PSA recurrence, independently of age and traditional clinicopathological variables.

Indexed as

Biomarkers, TumorDNA MethylationEpigenesis, GeneticNeoplasm Recurrence, LocalProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm GradingProstatectomyProstate-Specific AntigenBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID41266854
PMCPMC12852899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.